Imrecoxib manufacturers
- Imrecoxib
-
- $1.00 / 1g
-
2021-07-20
- CAS:395683-14-4
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- Imrecoxib USP/EP/BP
-
- $1.10 / 1g
-
2021-06-11
- CAS:395683-14-4
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Imrecoxib Basic information |
| Product Name: | Imrecoxib | | Synonyms: | Imrecoxib;Imrecoxib USP/EP/BP;2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl-;BAP 909,Cyclooxygenase,Inhibitor,COX,Imrecoxib,inhibit,BAP909 | | CAS: | 395683-14-4 | | MF: | C21H23NO3S | | MW: | 369.48 | | EINECS: | | | Product Categories: | | | Mol File: | 395683-14-4.mol |  |
| | Imrecoxib Chemical Properties |
| Boiling point | 604.1±55.0 °C(Predicted) | | density | 1?+-.0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (270.65 mM) | | pka | -2.25±0.60(Predicted) | | CAS DataBase Reference | 395683-14-4 |
| | Imrecoxib Usage And Synthesis |
| Clinical Use | Imrecoxib, a new non-steroid anti-inflammtory drug (NSAID), was launched in China with the trade
name of Hengyang® for the treatment of osteoarthritis in 2012. It was originally designed and
synthesized by Guo and co-workers at the Institute of Materia Medica (IMM) of the Chinese Academy
of Medical Sciences in collaboration with Hengrui Pharmaceuticals. Imrecoxib, which is a moderately
selective COX-2 inhibitor (with IC50 values against COX-1 and COX-2 being 115 ± 28 nM and 18 4
nM, respectively). | | Synthesis | Imrecoxib has had two synthetic routes reported across several publications. The most likely process-scale route to this drug is described in the scheme, which began with 2-bromo-4'-(methylsulfonyl)-acetophenone (84) and p-tolylacetic acid (85) as starting materials. In the
presence of base, |á-bromoketone 84 was treated with acid 85 which resulted in lactone 86 in 72% yield
across the two-step sequence. Exposure of lactone 86 with propylamine triggered a ring-opening-ring
closing reaction, which resulted in imrecoxib (XIII) directly in 85% yield. 
|
| | Imrecoxib Preparation Products And Raw materials |
|